Newly activated UI Cancer Center Clinical Trials

The following study has recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO). Please click on the link to learn about the details regarding the study on For more information or questions about the study, please email or call 312-355-5112.

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IV A, Stage IV B or Recurrent Endometrial Cancer

Sponsor: National Cancer Institute
Principal Investigator: Oana Danciu, MD

Translate »